ReviewJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society2018
The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis.
Review in Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms.Molecular neurobiology · 2026Article
- Influence of OSCAR-IB criteria on test-retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Visual impairment in multiple sclerosis involving post-geniculate gray and white matter: above and beyond.Frontiers in neurology · 2026Review
- Influence of OSCAR-IB Criteria on Test-Retest Reliability of Cirrus HD-OCT Retinal Thickness Measurements in People With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Macular OCT's Proficiency in Identifying Retrochiasmal Visual Pathway Lesions in Multiple Sclerosis-A Pilot Study.Diagnostics (Basel, Switzerland) · 2024Article
- Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis.PloS one · 2023Article
- Article
- APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies.Neurology · 2021Article
- [Differential diagnostics of autoimmune inflammatory spinal cord diseases].Der Nervenarzt · 2021Review
- Test-retest reliability of Cirrus HD-optical coherence tomography retinal layer thickness measurements in people with multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe International Multiple Sclerosis Visual System Consortium (IMSVISUAL) was formed in November 2014 with the primary goal of improving research, care, and education regarding the role of the visual system in multiple sclerosis (MS) and related disorders.
methodsIn this review, we describe the formation, goals, activities, and structure of IMSVISUAL, as well as the relationship of IMSVISUAL with the Americas Committee for Treatment and Research in MS (ACTRIMS). Finally, we provide an overview of the work IMSVISUAL has completed to date, as well as an outline of research projects ongoing under the auspices of IMSVISUAL.
resultsIMSVISUAL has 140 members worldwide and continues to grow. Through IMSVISUAL-related research, optical coherence tomography (OCT)-derived peripapillary retinal nerve fiber layer (pRNFL) thinning has been established as a predictor of future disability in MS. IMSVISUAL has also developed guidelines for reporting OCT studies in MS. Moreover, a systematic review performed by IMSVISUAL found that not only are pRNFL and ganglion cell + inner plexiform layer (GCIPL) thicknesses reduced in patients with MS (particularly in eyes with prior optic neuritis [ON]), but that inner nuclear layer measures may be higher among MS ON eyes, relative to healthy control eyes. Currently, there are several ongoing IMSVISUAL projects that will establish a role for visual outcomes in diagnosing MS and quantifying the effects of emerging therapies in clinical trials.
conclusionsThe development of IMSVISUAL represents a major collaborative commitment to defining the role of visual outcomes in high-quality, large-scale studies that generate definitive and instructive findings in the field of MS. As a consortium, IMSVISUAL has completed several international collaborative projects, is actively engaged in numerous ongoing research studies, and is committed to expanding the role of vision research in MS and related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.